文献速递免疫规划卫生政策与健康促进妇幼与学校卫生

日本孕期流感疫苗接种的成本效果分析

Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan.
PubMed 文献 · Vaccine · 2020-10-02

该研究采用决策树模型,从社会视角评估日本引入季节性孕期流感疫苗接种规划(AMVP)的成本效果。结果显示AMVP虽降低疾病治疗费用但无法抵消接种成本,增量QALY为0.00009(84.2%来自婴儿),ICER为¥7,779,356/US$70,721每QALY,在WHO建议的「成本效果」标准下具有成本效果。

要点

  • 孕期流感疫苗接种可减少母婴流感相关疾病治疗费用,但不足以抵消接种成本。
  • 增量QALY为0.00009,其中84.2%来自婴儿。
  • ICER为¥7,779,356/US$70,721每QALY,符合WHO建议的成本效果标准。

核心结论

  • 在日本从社会视角为孕妇接种流感疫苗以预防未接种婴儿及孕产妇流感相关疾病具有成本效果,符合WHO建议的「成本效果」标准(GDP的1-3倍)。

研究设计与样本

  • 估计孕妇/产后妇女或其婴儿因流感接受治疗的概率随日历时间、接种状态和/或孕周而变化。
  • 从社会视角计算与当前无AMVP相比的增量成本效果比(ICER)。
  • 转移概率、效用权重(用于估计QALY)和疾病治疗成本通过计算或文献提取获得。
  • 每次接种成本假设为¥3,529/US$32.1。

主要发现

  • AMVP降低疾病治疗费用,但减少额无法抵消接种成本。
  • 增量QALY为0.00009,其中84.2%来自婴儿。
  • ICER为¥7,779,356/US$70,721每QALY获得。
  • 单因素敏感性分析显示,婴儿疫苗效果和每次接种成本是影响ICER的两个主要关键变量。

关键数值与推荐

  • ICER为¥7,779,356/US$70,721每QALY获得。
  • 增量QALY为0.00009,其中84.2%来自婴儿。
  • 每次接种成本假设为¥3,529/US$32.1。

临床怎么用

  • 在决策是否将孕期流感疫苗接种纳入常规免疫规划时,可参考本研究的成本效果结果。
  • 婴儿疫苗效果和接种成本是影响成本效果的关键参数,实际应用中需关注这些参数的本土化取值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnant women and infants are known as high risk groups for influenza. WHO recommend pregnant women be vaccinated with inactivated influenza vaccine. In Japan, some municipalities started to give subsidy to encourage pregnant women to receive a shot on their own accord, which has made the introduction of seasonal antepartum maternal vaccination program (AMVP) into the routine vaccination list a current topic in health policy and has raised the need to evaluate the value for money of such possibility. METHODS: We conducted a cost-effectiveness analysis to evaluate the efficiency of conducting AMVP in Japan. A decision tree model was adopted taking into consideration the duration of single-year vaccine effectiveness for infants and for mothers. The program targeted pregnant women aged 20-49 years old at or over 12 weeks gestation during October 1 through March 30. Estimated probabilities of treatments received due to influenza for pregnant/postpartum women or their infants varied by calendar time, vaccination status, and/or gestational age. Incremental cost-effectiveness ratio (ICER) compared with current no-AMVP from societal perspective was calculated. Transition probabilities, utility weights to estimate quality-adjusted life year (QALY), and disease treatment costs were either calculated or extracted from literature. Costs per vaccination was assumed at ¥3,529/US$32.1. RESULTS: AMVP reduces disease treatment costs, while the reduction cannot offset the vaccination cost. Incremental QALYs were at 0.00009, among them 84.2% were from infants. ICER was ¥7,779,356/US$70,721 per QALY gained. One-way sensitivity analyses revealed that vaccine effectiveness for infant and costs per shot were the two main key variables affecting the ICER. CONCLUSION: We found that vaccinating pregnant women with influenza vaccine to prevent unvaccinated infants and pregnant/postpartum women from influenza-associated disease in Japan can be cost-effective from societal perspective, under the WHO-suggested "cost-effective" criteria (1-3 times of GDP).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hoshi SL, Shono A, Seposo X, et al. Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan. Vaccine. 2020. PMID: 33020012. doi:10.1016/j.vaccine.2020.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。